

PAOLO GONTERO

CURRICULUM VITAE

- Born in Ivrea (Torino), Italy, the 3th of June, 1968
- High school degree in Classical Studies in 1987
- Degree in Medicine and Surgery achieved the 26th of October 1993 at the University of Torino (Italy).
- Licence to practice as a doctor in Italy obtained in November 1993.
- Degree of Specialist in Urology obtained the 25th of November 1999 at the University of Studies of Torino.
- From 1998 he is a member of the General Medical Council (London, UK) and from 2003 he is registered as a Urologist in the Specialist Registry of the General Medical Council (London UK).
- Current position: **Chairmen Urology Department**, Città della Salute e della Scienza, San Giovanni Battista – Molinette Hospital, University of Studies of Torino, Torino, Italy.

PART 1: ACADEMIC AND SCIENTIFIC ACHIEVEMENTS

TITLES ACHIEVED AFTER THE UROLOGICAL TRAINING

- Specialist in Urology since the 25th of November 1999 at the University Training of Torino.
- **Lecturer in Urology** at the University of Piemonte Orientale, Novara, Italy from 3/2002 to 10/2006 and at the University of Studies of Torino from 10/2006 to 11/2010.
- Second Level Master degree in Surgical Andrology at the University of Torino.
- From the 1st of November 2003 to the 5th of May 2004 he has been a **Consultant Urologist** in the Department of Urology, St George Hospital, London, UK.
- Nominated **Associate Professor of Urology** at the University of Studies of Torino the 1st of November 2010, ongoing position
- Chairmen in charge of the Division of Urology 1, San Giovanni Battista University Hospital in Torino

from 1st of November to 20 of December 2010

- Present working position: **Chairmen** Department of Urology, Department of Surgical Sciences, Città della Salute e della Scienza, San Giovanni Battista University Hospital, University of Studies of Torino, Torino, Italy
- **Director** of Second Degree **Master in Urology Oncology** at the University of Studies of Torino
- **Scientific Director of the “Torino Prostate Project”**
- **Chairmen of the Course on “Small renal masses” at the European School of Urology**
- Member of the European Association of Urology Guidelines on NMIBC and UTUC
- Chairmen 2017 ICUD on Bladder Cancer for the Societè Internationale de Urologie

TRAINING AND POSITIONS IN FOREIGN COUNTRIES

6-8/1996 “Clinical Fellowship” at the Department of Urology,
Tampere University Hospital, Finland (Prof. T. Tammela).

1/98 – 3/99 “Research Registrar” and “Specialist Registrar” in Urology at King’s College Hospital, London.

8/99 - 10/99 “Specialist Registrar” in Urology at Medway Maritime Hospital, Kent, UK

1/2000 - 4/2000 Staff Grade at the Department of Urology, Medway Maritime Hospital,
Kent, UK

28/8/2001 – 12/9/2001 Staff Grade at the Department of Urology, Medway Maritime
Hospital, Kent, UK

1/9/2002 – 18/9/2002 Staff Grade in Urology at the Department of Urology, Medway
Maritime Hospital, Kent, UK

1/11/2003 – 05/05/2004 Consultant Urologist, St George Hospital, London, UK

1/5 – 25/5/2006 Stage on cystectomy and urinary diversions at the Urology Department,
University of Mansoura, Egypt.

5/8 – 26/8/2006 Stage on open radical prostatectomy at the Department of Urology,
Catholic University of Leuven, Belgium

POSITIONS

5/94-11/97 National Communicating Officer for the European Society of Residents

in Urology (ESRU, formerly EBUT)

3/98 Member of the Scientific Comity in the Vth International Meeting of the ESRU held during the EAU Congress (Barcelona 21/3/98)

2000 – (ongoing position) Full member of the European Organization of Research and Treatment of Cancer, GU Group (EORTC GU)

2007- 2010 Secretary of the Italian Research Foundation in Urology L.U.N.A

2007 – (ongoing position) Lecturer at the European School of Urology (ESU)

2010 – 2011 Director of the II° level Course on Urological Rehabilitation, University of Studies of Torino

2009 - (ongoing position) Director of the II° level Master Degree in Prostate Cancer Oncology for Specialists in Urology, University of Studies of Torino

2012 – (ongoing position) Chairmen of the Course on “Small renal masse” at the European School of Urology

CURRENT TEACHING COMMITMENTS (ITALY)

- Professor of Urology and course director at the School of Medicine, University of Studies of Torino (Channel B) since 2010 (ongoing position)
- Professor in charge of the B Canal and D Canal for the discipline “Urology” at the School of Nurse Sciences, University of Studies of Torino
- Professor of Urology for the following postgraduate training programmes at the University of Studies of Torino:
 - Obstetrics and Gynaecology
 - Nephrology
 - Medical Oncology
 - Urology
 - Radiology and Radiotherapy
- Professor at the following second level Master degrees, University of Studies of Torino:
 - Prostatic Oncology
 - Surgical Andrology
 - Laparoscopy
 - Theatre Assistant

CURRENT AND PREVIOUS TEACHING COMMITMENTS ABROAD

- Lecturer at the School of Medicine, King’s College Hospital, London, UK between 2/1998 – 3/1999

- Lecturer at the School of Medicine, St George Hospital, London, UK, from 10/2003 to 5/2004 (as a Consultant Urologist)
- **Lecturer at the European School of Urology** from 2007 (ongoing position) and Chairmen of the ESU course on “Small renal masses” from 2012 (ongoing position)

REVIEWER ACTIVITY

- Member of the Editorial Committee of the following Journals:

- Archivio Espanol de Urologia
- Archivio Italiano di Urologia e Andrologia
- Minerva Urologica e Nefrologica
- Urologia (former Deputy Editor)

- Reviewer of the following International Journals:

- European Urology
- Journal of Sexual Medicine
- British Journal of Urology Int
- Journal of Urology
- Prostate Cancer and Prostatic Diseases
- European Journal of Cancer

- Awarded as “Best reviewer 2016” by the Journal Urology

PUBLISHED PAPERS

Authors or co-author of more than 250 papers:

- 171 original papers on international peer reviewed journals with impact factor
- 5 “Letters” on international journals
- 11 papers on indexed journals but no impact factor
- 70 papers on journals not indexed and without impact factor

Papers with Impact Factor

173) Witjes JA, **Gontero P**, Dalbagni G, Karnes JR, Shariat S, Joniau S, Palou J, Serretta V, Larré S, Stasi S, Colombo R, Babjuk M, Dalbagni G, Sylvester R. The efficacy of BCG Tice and BCG Connaught in a cohort of 2099 T1G3 non-muscle invasive bladder cancer patients. *Urol Oncol*, in press **IF 2.92**

172) Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Zattoni F, Karnes RJ, **Gontero P**. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy. *Eur Urol Focus*, in press.

171) Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma S, Preto M, **Gontero P**, Cucchiarale C, Lurkin I, Zwarthoff E, Vineis P, Sacerdote C, Matullo G, Naccarati A. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. *Oncotarget Journal*, in press **IF 5.008**

170) Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, **Gontero P**, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. *J Surg Oncol*. 2016 Aug 26. doi: 10.1002/jso.24395. [Epub ahead of print] **IF 3.15**

169) Falcone M, Timpano M, Ceruti C, Sedigh O, Oderda M, Gillo A, Preto M, Sibona M, Garaffa G, **Gontero P**, Frea B, Rolle L. A Single-center Analysis on the Learning Curve of Male-to-Female Penoscrotal Vaginoplasty by Multiple Surgical Measures. *Urology*. 2016 Jul 18. pii: S0090-4295(16)30412-5. doi: 10.1016/j.urology.2016.07.012. [Epub ahead of print] PubMed PMID: 27443465. **IF 2.18**

168) Turinetto V, Pardini B, Allione A, Fiorito G, Viberti C, Guarrera S, Russo A, Anglesio S, Ruo Redda MG, Casetta G, Cucchiarale G, Destefanis P, Oderda M, **Gontero P**, Rolle L, Frea B, Vineis P, Sacerdote C, Giachino C, Matullo G. H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer. *Mol Carcinog*. 2015 Nov 19. doi: 10.1002/mc.22431. [Epub ahead of print] PubMed PMID: 27439749. **IF 4.72**

167) Marra G, **Gontero P**, Valerio M. Changing the prostate cancer management pathway: why Focal Therapy is a step forward. *Arch Esp Urol*. 2016 Jul;69(6):271-280. PubMed PMID: 27416630. **IF 0.307**

166) Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, Mantini G, Gontero P, Savoca G, Ficarra V; L. U. N. A. Foundation, and Società Italiana d'Urologia. Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOIng Treatment for Prostate canCER (CHOICE)

Study. *Urology*. 2016 Jul 8. pii: S0090-4295(16)30315-6. doi: 10.1016/j.urology.2016.06.024. [Epub ahead of print] PubMed PMID: 27402374.

IF 2.18

165) Volante M, Tota D, Giorcelli J, Bollito E, Napoli F, Vatrano S, Buttigliero C, Molinaro L, **Gontero P**, Porpiglia F, Tucci M, Papotti M, Berruti A, Rapa I. Androgen deprivation modulates gene expression profile along prostate cancer progression. *Hum Pathol*. 2016 Jun 21. pii: S0046-8177(16)30119-8. doi: 10.1016/j.humphath.2016.06.004. [Epub ahead of print] PubMed PMID: 27342909.

IF 2.79

164) Oderda M, Faletti R, Battisti G, Dalmaso E, Falcone M, Marra G, Palazzetti A, Zitella A, Bergamasco L, Gandini G, **Gontero P**. Prostate Cancer Detection Rate with Koelis Fusion Biopsies versus Cognitive Biopsies: A Comparative Study. *Urol Int*. 2016 Jun 4. [Epub ahead of print] PubMed PMID: 27256369.

IF 1.31

163) Faletti R, Battisti G, Discalzi A, Grognerdi ML, Martinello S, Oderda M, Gontero P, Bergamasco L, Cassinis MC, Fonio P. Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer? *Abdom Radiol (NY)*. 2016 May;41(5):926-33. doi: 10.1007/s00261-015-0574-x. PubMed PMID: 27193791.

IF 2.18

162) Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. *World J Urol*. 2016 Feb 20. [Epub ahead of print] PubMed PMID: 26897499.

IF 2.39

161) Sylvester R, Gontero P, Oddens J. Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. *Eur Urol* 2016;69:60-9. *Eur Urol*. 2016 Feb 10. pii: S0302-2838(16)00175-5. doi: 10.1016/j.eururo.2016.01.055. [Epub ahead of print] PubMed PMID: 26874805.

IF 14.9

160) Soria F, Allasia M, Oderda M, Gontero P. Hyperthermia for non-muscle invasive bladder cancer. *Expert Rev Anticancer Ther*. 2016 Mar;16(3):313-21. doi: 10.1586/14737140.2016.1135743. Epub 2016 Jan 21. PubMed PMID: 26713510.

IF 2.09

159) Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. *Urol Oncol*. 2015 Dec 16. pii: S1078-1439(15)00570-0. doi: 10.1016/j.urolonc.2015.11.018. [Epub ahead of print] PubMed PMID: 26706120.

IF 2.92

158) Grange C, Tapparo M, Tritta S, Deregibus MC, Battaglia A, Gontero P, Frea B, Camussi G. Role of HLA-G and extracellular vesicles in renal cancer stem cell-induced inhibition of dendritic cell

differentiation. *BMC Cancer*. 2015 Dec 24;15(1):1009. doi: 10.1186/s12885-015-2025-z. PubMed PMID: 26704308; PubMed Central PMCID: PMC4690241.

IF 3.26

157) Rolle L, Falcone M, Ceruti C, Timpano M, Sedigh O, Ralph DJ, Kuehhas F, Oderda M, Preto M, Sibona M, Gillo A, Garaffa G, Gontero P, Frea B. A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the 'sliding' technique for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction. *BJU Int*. 2015 Dec 21. doi: 10.1111/bju.13371. [Epub ahead of print] PubMed PMID: 26688436.

IF 4.38

156) Oderda M, Maletta F, Palazzetti A, Faletti R, Falcone M, Marra G, Galliano D, Davico Bonino L, Gontero P. Tubulocystic renal cell carcinoma disguised as a renal cyst. *Minerva Urol Nefrol*. 2015 Dec 18. [Epub ahead of print] PubMed PMID: 26684179.

IF 0.53

155) Palazzetti A, Oderda M, Falcone M, Cassenti A, Delsedime L, Frea B, Pacchioni D, Gontero P. Osteoclast-Like Giant Cell Carcinoma Hidden by a Bladder Stone in a Patient With Neurogenic Bladder. *Clin Genitourin Cancer*. 2016 Feb;14(1):e127-30. doi: 10.1016/j.clgc.2015.10.004. Epub 2015 Oct 20. PubMed PMID: 26520428. **IF 2.55**

154) **Gontero P**, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmström PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. *BJU Int*. 2015 Oct 15. doi: 10.1111/bju.13354. [Epub ahead of print] PubMed PMID: 26469362. **IF 4.38**

153) Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, 152) Mantini G, **Gontero P**, Savoca G, Ficarra V; (Members of the LUNA Foundation, Società Italiana d'Urologia). Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. *BJU Int*. 2015 Aug 31. doi: 10.1111/bju.13307. [Epub ahead of print] PubMed PMID: 26332130. **IF 4.38**

151) Sedigh O, Falcone M, Ceruti C, Timpano M, Preto M, Oderda M, Kuehhas F, Sibona M, Gillo A, Gontero P, Rolle L, Frea B. Sexual function after surgical treatment for penile cancer: Which organ-sparing approach gives the best results? *Can Urol Assoc J*. 2015 Jul-Aug;9(7-8):E423-7. doi: 10.5489/cuaj.2801. PubMed PMID: 26279710.

IF 0.86

150) Pisano F, Falcone M, Abbona A, Oderda M, Soria F, Peraldo F, Marson F, Barale M, Fiorito C, Gurioli A, Frea B, **Gontero P**. The importance of psychosexual counselling in the re-establishment of organic and erotic functions after penile prosthesis implantation. *Int J Impot Res*. 2015 Aug 13. doi: 10.1038/ijir.2015.17. [Epub ahead of print] PubMed PMID: 26268774.

IF 1.39

149) Cambier S, Sylvester RJ, Collette L, **Gontero P**, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. *Eur Urol*. 2015 Jul 22. pii: S0302-2838(15)00556-4. doi: 10.1016/j.eururo.2015.06.045. [Epub ahead of print] PubMed PMID: 26210894.

IF 14.9

148) Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, **Gontero P**. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: Time for a bespoke approach? *Int J Urol*. 2015 Jul 14. doi: 10.1111/iju.12866. [Epub ahead of print] PubMed PMID: 26177667.

IF 1.87

147) Khadjavi A, Mannu F, Destefanis P, Sacerdote C, Battaglia A, Allasia M, Fontana D, Frea B, Polidoro S, Fiorito G, Matullo G, Pantaleo A, Notarpietro A, Prato M, Castagno F, Vineis P, **Gontero P**, Giribaldi G, Turrini F. Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins. *Br J Cancer*. 2015 Jul 28;113(3):469-75. doi: 10.1038/bjc.2015.232. Epub 2015 Jun 30. PubMed PMID: 26125446; PubMed Central PMCID: PMC4522638.

IF

5.56

146) Barale M, Oderda M, Faletti R, Falcone M, Pisano F, Marra G, Cassenti A, Delsedime L, Pacchioni D, **Gontero P**. The strange case of a hematocele mistaken for a neoplastic scrotal mass. *Can Urol Assoc J*. 2015 Mar-Apr;9(3-4):E217-9. doi: 10.5489/cuaj.2630. PubMed PMID: 26085884; PubMed Central PMCID: PMC4455644.

IF 0.86

145) Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, Pagliarulo V, Dosio F, **Gontero P**. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study. *World J Urol*. 2015 May 31. [Epub ahead of print] PubMed PMID: 26026818.

IF 2.39

144) **Gontero P**, Marra G, Soria F, Oderda M, Zitella A, Baratta F, Chiorino G, Gregnanin I, Daniele L, Cattel L, Frea B, Brusa P. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"? *Prostate*. 2015 Aug;75(11):1177-86. doi: 10.1002/pros.22999. Epub 2015 Apr 20. PubMed PMID: 25893930.

IF 3.77

143) Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, **Gontero P**, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Verghe D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. *J Urol*. 2015 Aug;194(2):304-9. doi: 10.1016/j.juro.2015.02.2948. Epub 2015 Mar 19. PubMed PMID: 25797392.

IF 4.7

142) Timpano M, Falcone M, Kuehhas F, Ceruti C, Sedigh O, Oderda M, Gontero P, Frea B, Rolle L. Surgical management of hypogonadic patients with hypotrophic testicles and small penis: a novel, combined technique with an infrapubic approach. *Asian J Androl*. 2015 Mar 10. doi: 10.4103/1008-

682X.145431. [Epub ahead of print] PubMed PMID: 25761832.

IF 2.64

141) Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F, Joniau S; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Natural history of surgically treated high-risk prostate cancer. *Urol Oncol*. 2015 Feb 6. pii: S1078-1439(14)00439-6. **IF 2.92**

140) Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, Briganti A, Montorsi F, Van Poppel H, Joniau S, Spahn M. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. *Prostate Cancer Prostatic Dis*. 2015 Mar;18(1):31-7. **IF 3.80**

139) Crobeddu E, Garbossa D, Piloni G, Bozzaro M, Berjano P, Gontero P, Fiorito C, Panciani PP, Spena G, Zenga F, Tartara F, Fontanella M, Ducati A. Management of vascular and ureteral complications after lumbar discectomy. *J Neurosurg Sci*. 2014 Jun;58 (2 Suppl 1):107-12. **IF 1.39**

138) Cai T, Pisano F, Magri V, Verze P, Mondaini N, D'Elia C, Malossini G, Mazzoli S, Perletti G, Gontero P, Mirone V, Bartoletti R. Chlamydia trachomatis infection is related to premature ejaculation in chronic prostatitis patients: results from a cross-sectional study. *J Sex Med* 2014 Dec;11(12):3085-92. **IF 3.15**

137) Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, Barbareschi M, Brausi M, Gacci M, Luciani LG, Liguori G, Gontero P, Campodonico F, Simonato A, Boddi V, Di Stasi SM, Colombo R, Serretta V, Carmignani G, Malossini G, Altieri V, Carini M, Terrone C, Bassi P, Montorsi F, Ficarra V, Selli C, Mirone V, Bartoletti R. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. *Urology* 2014;84(5):1141-6. **IF 2.18**

136) Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G. Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer. *Cancer Epidemiol Biomarkers Prev*. 2014 Nov;23(11):2439-46. **IF 3.62**

135) Racioppi M, Salmaso L, Brombin C, Arboretti R, D'Agostino D, Colombo R, Serretta V, Brausi M, Casetta G, Gontero P, Hurle R, Tenaglia R, Altieri V, Bartoletti R, Maffezzini M, Siracusano S, Morgia G, Bassi PF. The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome. *Urol Int*. 2015;94(3):262-9. **IF 1.31**

134) Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, **Gontero P**, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. *J Urol*. 2015 Feb;193(2):436-42. **IF 4.7**

133) **Gontero P**, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeny LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. *Eur Urol.* 2015 Jan;67(1):74-82. **IF 14.97**

132) Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D. Clinical and Cost Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence Review and Updated Expert Recommendations. *Eur Urol.* 2014 Nov; 66(5):863-871. **IF 14.97**

131) Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, **Gontero P**; for the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. *Eur Urol.* 2014 Mar 21. pii: S0302-2838(14)00249-8. doi: 10.1016/j.eururo.2014.03.013. [Epub ahead of print] **IF 14.97**

130) Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, **Gontero P**, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, 129) Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep.* 2014 May;15(5):404. **IF 1.59**

128) D'Amelio P, Roato I, Oderda M, Soria F, Zitella A, Ferracini R, Mengozzi G, **Gontero P**, Isaia GC. DKK-1 in prostate cancer diagnosis and follow up. *BMC Clin Pathol.* 2014 Mar 21;14(1):11. **IF 2.13**

127) Miano R, De Nunzio C, Kim FJ, Rocco B, **Gontero P**, Vicentini C, Micali S, Oderda M, Masciovecchio S, Asimakopoulos AD. Transperineal versus transrectal prostate biopsy for predicting the final laterality of prostate cancer: are they reliable enough to select patients for focal therapy? Results from a multicenter international study. *Int Braz J Urol.* 2014 Jan-Feb;40(1):16-22. **IF 0.87**

126) Fasolis M, Zavattero E, Sedigh O, **Gontero P**, Preto M, Frea B, Ramieri G. Oral mucosa harvest for urologic reconstruction: role of maxillofacial surgeon and donor-site morbidity evaluation. *J Craniofac Surg.* 2014 Mar;25(2):604-6. **IF 0.7**

125) Cai T, Gacci M, Mattivi F, Mondaini N, Migno S, Boddi V, Gacci P, Detti B, **Gontero P**, Chiadini S, Mereu L, Tateo S, Mazzoli S, Malossini G, Bartoletti R. Apple consumption is related to better sexual quality of life in young women. *Arch Gynecol Obstet.* 2014 Jul;290(1):93-8. **IF 1.68**

124) Joniau S, Briganti A, **Gontero P**, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-

institutional Study. *Eur Urol.* 2015 Jan;67(1):157-64.
14.9

IF

123) Milla P, Fiorito C, Soria F, Arpicco S, Cattel L, Gontero P. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients. *Cancer Chemother Pharmacol.* 2014 Mar;73(3):503-9.

IF 2.82

122) Rolle L, Falcone M, Vighetti S, Ceruti C, Sedigh O, Timpano M, Molo MT, Castelli L, Preto M, Gontero P, Frea B. Does sex reassignment surgery induce cerebral modifications in MTF transsexuals? *J Sex Med.* 2014 Jan;11(1):312.

IF 2.84

121) Bertoldo U, **Gontero P**, Varetto G, Garneri P, Castagno C, Oderda M, Soria F, Rispoli P. Renal artery aneurysm treated with laparoscopic nephrectomy, ex vivo repair and autotransplantation. *J Cardiovasc Surg (Torino).* 2014;55(2):299-301.

IF: 1.63

120) Muller B, van den Bos W, Brausi M, Cornud F, **Gontero P**, Kirkham A, Pinto P, Polascik TJ, Rastinehad AR, de Reijke T, de la Rosette J, Ukimura O, Villers A, Walz J, Wijkstra H, Marberger M. The Role of Multiparametric Magnetic Resonance Imaging in Focal Therapy for Prostate Cancer: A Delphi Consensus Project. *BJU* 2014 Nov;114(5):698-707.

IF: 4.38

119) **Gontero P**, Gillo A, Fiorito C, Oderda M, Pacchioni D, Casetta G, Peraldo F, Zitella A, Tizzani A, Ricceri F. Prognostic Factors of 'High-Grade' Ta Bladder Cancers according to the WHO 2004 Classification: Are These Equivalent to 'High-Risk' Non-Muscle-Invasive Bladder Cancer? *Urol Int.* 2014;92(2):136-42.

IF: 1.31

118) Botticella A, Guarneri A, Filippi AR, Levra NG, Munoz F, Ragona R, **Gontero P**, Ricardi U. May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy? *J Cancer Res Clin Oncol.* 2013;139(11):1955-60.

IF: 3.14

117) **Gontero P**, Spahn M, Marchioro G, Karnes JR, Briganti A, Frea B, Ricardi U, van Poppel H, Joniau S. Salvage Radical Prostatectomy in Nonmetastatic Castration-resistant Prostate Cancer Patients Who Received Previous Radiotherapy: A Feasibility Study. *Eur Urol.* 2014;65(1):254-5.

IF: 14.976

116) Giribaldi G, Barbero G, Mandili G, Daniele L, Khadjavi A, Notarpietro A, Ulliers D, Prato M, Minero VG, Battaglia A, Allasia M, Bosio A, Sapino A, **Gontero P**, Frea B, Fontana D, Destefanis P. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma. *J Proteomics.* 2013;91:385-92.

IF: 3.86

115) Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, **Gontero P**, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG. *Eur Urol.* 2014;65(1):69-76.

IF: 14.976

114) Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, **Gontero P**, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk

CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. *Eur Urol.* 2013 Jul 10. pii: S0302-2838(13)00663-5. doi: 10.1016/j.eururo.2013.06.048. [Epub ahead of print] **IF: 14.976**

113) Gacci M, Simonato A, Lanciotti M, Ennas M, Varca V, Maffezzini M, Imbimbo C, **Gontero P**, Schiavina R, Carini M, Martorana G, Nicita G, Mirone V, Carmignani G. The impact of prior TURP on radical prostatectomy surgical margins: a multicenter analysis. *Urol Int.* 2013;91(1):62-8. **IF: 1.31**

112) Joniau S, Tosco L, Briganti A, Vanden Broeck T, **Gontero P**, Karnes RJ, Spahn M, Van Poppel H; European Multicenter Prostate Cancer Clinical and Translational research group. Results of surgery for high-risk prostate cancer. *Curr Opin Urol.* 2013 Jul;23(4):342-8. **IF: 2.006**

111) Gandaglia G, Briganti A, **Gontero P**, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). *BJU Int.* 2013;112(4):432-41. **IF: 4.387**

110) Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H; European Multicenter Prostate Cancer Clinical and Translational research Group (EMPaCT). Current role of surgery for high risk prostate cancer. *Arch Esp Urol.* 2013;66(3):259-73. **IF: 0.307**

109) Sacerdote C, Guarrera S, Ricceri F, Pardini B, Polidoro S, Allione A, Critelli R, Russo A, Andrew AS, Ye Y, Wu X, Kiemeny LA, Bosio A, Casetta G, Cucchiara G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Vineis P, Matullo G. Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy. *Int J Cancer.* 2013 Oct 15;133(8):2004-9. **IF: 5.53**

108) Guarneri A, Botticella A, Filippi AR, Ruggieri A, Piva C, Munoz F, Ragona R, Gontero P, Ricardi U. Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. *J Cancer Res Clin Oncol.* 2013 Jul;139(7):1141-7. **IF: 3.14**

107) **Gontero P**, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F. The impact of intravesical Gemcitabine and 1/3 dose Bacillus Calmette Guerin instillation therapy on the quality of life in non-muscle-invasive bladder cancer patients: results of a prospective, randomized phase II trial. *J Urol.* 2013 Sep;190(3):857-62. **IF: 4.7**

106) Tombal B, Andriole GL, de la Taille A, **Gontero P**, Haese A, Remzi M, Speakman M, Smets L, Stoevelaar H. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? *Urology.* 2013 May;81(5):998-1004. **IF: 2.18**

105) Brusa D, Simone M, **Gontero P**, Spadi R, Racca P, Micari J, Degiuli M, Carletto S, Tizzani A, Matera L. Circulating immunosuppressive cells of prostate cancer patients before and after radical

prostatectomy: Profile comparison. *Int J Urol*. 2013 Oct;20(10):971-8.

IF: 1.87

104) Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, **Gontero P**, Lotan Y, Chun FK, Fisch M, Scherr DS, Shariat SF. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol*. 2013 Aug;190(2):480-6. **IF: 4.7**

103) Oderda M, Ricceri F, Pisano F, Fiorito C, Gurioli A, Casetta G, Zitella A, Pacchioni D, **Gontero P**. Prognostic factors including Ki-67 and p53 in Bacillus Calmette-Guérin-treated non-muscle-invasive bladder cancer: a prospective study. *Urol Int*. 2013;90(2):184-90.

IF: 1.31

102) Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, **Gontero P**, Chun FK, Fisch M, Scherr DS, Shariat SF. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2013 Oct;31(5):1029-36.

IF: 2.39

101) Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, **Gontero P**, Hoeldt W, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. *Eur Urol*. 2013 Mar;63(3):462-72

IF: 14.97

100) **Gontero P**, Joniau S, Oderda M, Ruutu M, Van Poppel H, Laguna MP, de la Rosette J, Kirkali Z. Active surveillance for small renal tumors: Have clinical concerns been addressed so far? *Int J Urol*. 2013 Apr;20(4):356-61. **IF: 1.87**

99) Oderda M, Mondaini N, Bartoletti R, Vigna D, Fiorito C, Marson F, Peraldo F, Bosio A, Maletta F, Pacchioni D, **Gontero P**. Leiomyomata of the genitourinary tract: A case series from the "rare urological neoplasm" registry. *Scand J Urol Nephrol*. 2013 Apr;47(2):158-62

IF: 1.24

98) Briganti A, Spahn M, Joniau S, **Gontero P**, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. 2013 Apr;63(4):693-701. **IF: 14.97**

97) Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, **Gontero P**, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, Shariat SF; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2013 Mar;111(3 Pt B):E30-6. **IF: 4.38**

96) Guarneri A, Botticella A, Ragona R, Filippi AR, Munoz F, Casetta G, **Gontero P**, Tizzani A, Ricardi U. Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. *World J Urol*. 2013 Apr;31(2):411-5.] **IF: 2.39**

95) Bartoletti R, Meliani E, Simonato A, **Gontero P**, Berta G, Dalla Palma P, Leonardi E, Cai T, Carmignani G. Microwave-induced thermoablation with Amica-probe is a safe and reproducible method to treat solid renal masses: results from a phase I study. *Oncol Rep.* 2012;28(4):1243-8.

IF: 2.48

94) **Gontero P**, Sun M, Antonelli A, Bertini R, Carini M, Carmignani G, Longo N, Martorana G, Minervini A, Mirone V, Morgia G, Novara G, Oderda M, Simeone C, Simonato A, Siracusano S, Tizzani A, Volpe A, Karakiewicz P, Ficarra V; Members of the SATURN Project–LUNA Foundation. External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma. *World J Urol.* 2013 Oct;31(5):1285-90.

IF: 2.39

93) Simonato A, Varca V, Gacci M, **Gontero P**, De Cobelli O, Maffezzini M, Salvioni R, Carini M, Decensi A, Mirone V, Carmignani G. Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. *Adv Urol.* 2012 :651061. Epub 2012 May 15.

IF: 1.36

92) Oderda M, Cattaneo E, Soria F, Barreca A, Chiusa L, Morelli B, Zitella A, **Gontero P**. Adrenal ganglioneuroma with multifocal retroperitoneal extension: a challenging diagnosis. *ScientificWorldJournal.* 2011;11:1548-53.

IF: 1.21

91) Siracusano S, Novara G, Antonelli A, Artibani W, Bertini R, Carini M, Carmignani G, Ciciliato S, Cunico SC, Lampropoulou N, Longo N, Martorana G, Minervini A, Mirone V, Simeone C, Simonato A, Valotto C, Zattoni F, Ficarra V; members of the SATURN Project - LUNA Foundation. Prognostic role of tumour multifocality in renal cell carcinoma. *BJU Int.* 2012 Dec;110(11 Pt B):E443-8.

IF: 4.38

90) Spahn M, Briganti A, Capitanio U, Kneitz B, **Gontero P**, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Outcome Predictors of Radical Prostatectomy Followed by Adjuvant Androgen Deprivation in Patients with Clinical High Risk Prostate Cancer and pT3 Surgical Margin Positive Disease. *J Urol.* 2012 Jul;188(1):84-90. Epub 2012 May 12.

IF: 4.7

89) Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. *Adv Urol.* 2012.

IF: 1.36

88) Joniau S, Hsu CY, Gontero P, Spahn M, Van Poppel H. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. *Scand J Urol Nephrol.* 2012 Jun;46(3):164-71. Epub 2012 Feb 27.

IF: 1.24

87) Oderda M, Joniau S, Spahn M, **Gontero P**. Debulking surgery in the setting of very high-risk prostate cancer scenarios. *BJU Int.* 2012 Feb 7.

IF: 4.387

86) **Gontero P**, Oderda M, Filippini C, Fontana F, Lazzarich E, Stratta P, Turello E, Tizzani A, Frea B. Does kidney transplantation onto the external iliac artery affect the haemodynamic parameters of the

cavernosal arteries? Asian J Androl. 2011 Dec 26.

IF: 2.644

85) Brusa D, Carletto S, Cucchiarale G, Gontero P, Greco A, Simone M, Ferrando U, Tizzani A, Matera L. Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes. Prostate. 2011 Mar 1;71(4):344-52.

IF: 3.77

84) Briganti A, Joniau S, **Gontero P**, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer. Eur Urol. 2011 Dec 2.

IF: 14.97

83) Brausi MA, **Gontero P**, Altieri V, Colombo R, Conti I, Bono AV. Can Gemcitabine Instillation Ablate Solitary Low-Risk Non-Muscle-Invasive Bladder Cancer? Results of a Phase II Marker Lesion Study. Urol Int. 2011;87(4):470-4.

IF: 1.31

82) Van Baelen A, Mottet N, Spahn M, Briganti A, **Gontero P**, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. Adv Urol. 2012;2012:983058.

IF: 1.36

81) Joniau S, Tsivian M, **Gontero P**. Radiofrequency ablation for the treatment of small renal masses: safety and oncologic efficacy. Minerva Urol Nefrol. 2011 Sep;63(3):227-36.

IF: 0.536

80) Repetto L, Oderda M, Soria F, Pisano F, Besso L, Pasquale G, Tizzani A, **Gontero P**. Retroperitoneal laparoscopic kidney biopsy: technical tips for a minimally invasive approach. J Endourol. 2011 Oct;25(10):1639-42.

IF: 2.107

79) Oderda M, Mondaini N, **Gontero P**. Advice on the counseling of patients seeking treatment for short penis. BJU Int. 2011 Oct;108(7):1039-40

IF: 4.387

78) Civardi C, Collini A, **Gontero P**, Monaco F. Vasogenic erectile dysfunction Topiramate-induced. Clin Neurol Neurosurg. 2012 Jan;114(1):70-1.

IF: 1.198

77) Gacci M, Carini M, Simonato A, Imbimbo C, **Gontero P**, Briganti A, De Cobelli O, Fulcoli V, Martorana G, Nicita G, Mirone V, Carmignani G. Factors predicting continence recovery 1 month after radical prostatectomy: results of a multicenter survey. Int J Urol. 2011 Oct;18(10):700-8.

IF: 1.878

76) Tombal B, Ameye F, de la Taille A, de Reijke T, **Gontero P**, Haese A, Kil P, Perrin P, Remzi M, Schröder J, Speakman M, Volpe A, Meesen B, Stoevelaar H. Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. World J Urol. 2011 Jul 1.

IF: 2.397

75) Ricardi U, **Gontero P**, Ciammella P, Badellino S, Valentino F, Munoz F, Guarneri A, Rondi N, Moretto F, Filippi AR, Ragona R, Tizzani A. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med. 2010 Aug;7(8):2851-9.

IF: 2.844

78) **Gontero P**, Fiorito C, Oderda M, Pappagallo G, Brausi M. Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: What does an aborted trial tell us? *Urol Oncol*. 2011 May 6.

IF: 2.921

74) de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, **Gontero P**, Mottaz A, Haese A. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. *J Urol*. 2011 Jun;185(6):2119-25.

IF: 4.7

73) Oderda M, Ruoppolo M, Marson F, Pisano F, Fragapane G, Molinaro L, Pacchioni D, Tizzani A, **Gontero P**. Pathological features and adverse prognosis of a contemporary series of neuroendocrine bladder tumours. *Urol Int*. 2011;86(2):185-90.

IF: 1.31

72) **Gontero P**, Spahn M, Tombal B, Bader P, Hsu CY, Marchioro G, Frea B, Van Der Eeckt K, Kneitz B, Frohneberg D, Tizzani A, Van Poppel H, Joniau S. Is there a prostate-specific antigen upper limit for radical prostatectomy? *BJU Int*. 2011 Oct;108(7):1093-100.

IF: 4.387

71) Oderda M, Zitella A, Richiardi L, Tizzani A, **Gontero P**. Effect of finasteride on the sensitivity of PSA to detect prostate cancer in rebiopsy series. *Arch Ital Urol Androl*. 2010;82(4):135-8.

IF: 0.91

70) Imbimbo C, Creta M, Gacci M, Simonato A, **Gontero P**, de Cobelli O, Briganti A, Fulcoli V, Martorana G, Nicita G, Mirone V, Carmignani G. Patients' desire to preserve sexual activity and final decision for a nerve-sparing approach: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. *J Sex Med*. 2011;8(5):1495-502.

IF: 2.84

69) Cai T, Mondaini N, Migno S, Meacci F, Boddi V, **Gontero P**, Malossini G, Geppetti P, Mazzoli S, Bartoletti R. Genital Chlamydia trachomatis infection is related to poor sexual quality of life in young sexually active women. *J Sex Med*. 2011;8(4):1131-7.

IF: 2.84

68) **Gontero P**, Oderda M, Altieri V, Bartoletti R, Cai T, Colombo R, Curotto A, Di Stasi S, Maffezzini M, Tamagno S, Serretta V, Sogni F, Terrone C, Tizzani A, Morgia G, Mirone V, Carmignani G. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antitubercular therapy Italian study. *Urol Int*. 2011 Feb;86(1):19-24.

IF: 1.31

67) Tailly T, Goeman L, **Gontero P**, Joniau S. The safety and oncologic efficacy of radio-frequency ablation for the treatment of small renal masses: comprehensive review of the current literature. *Panminerva Med*. 2010 Dec;52(4):319-29. Review.

IF: 1.6

66) Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, **Gontero P**, Irani J, Chun FK. External Validation of Urinary PCA3 Based Nomograms to Individually Predict Prostate Biopsy Outcome. *Eur Urol* 2010 Jul 3 [Epub ahead of print].

IF: 14.976

65) **Gontero P**, Cattel L, Paone TC, Milla P, Berta G, Fiorito C, Carbone F, Medana C, Tizzani A. Pharmacokinetics study to optimize the intravesical administration of gemcitabine. *BJU Int*. 2010 Jun 30. [Epub ahead of print].

IF: 4.387

- 64) Joniau S, Tailly T, Goeman L, Blyweert W, **Gontero P**, Joyce A. Kidney radiofrequency ablation for small renal tumors: oncologic efficacy. **J Endourol.** 2010 May;24(5):721-8. Review.
IF: 2.107
- 63) Gianino MM, Galzerano M, Martin B, Chiadò Piat S, **Gontero P**. Costs in Surgical Techniques for Radical Prostatectomy: A Review of the Current State. *Urol Int.* 2010 May 7. [Epub ahead of print].
IF: 1.313
- 62) Bartoletti R, Cai T, Tosoratti N, Amabile C, Crisci A, Tinacci G, Mondaini N, **Gontero P**, Gelsomino S, Nesi G. In vivo microwave-induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. *BJU Int.* 2010 Mar 23. [Epub ahead of print].
IF: 4.387
- 61) Spahn M, Joniau S, **Gontero P**, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Tizzani A, Van Poppel H. Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients. *Eur Urol.* 2010 Mar 17. [Epub ahead of print].
IF: 14.976
- 60) Oderda M, Michelon F, Appendino M, Gallo M, Senetta R, Pacchioni D, Tizzani A, **Gontero P**. Primary bladder pheochromocytoma diagnosed by a vet. *Scand J Urol Nephrol.* 2010 Apr;44(3):186-9.
IF: 1.243
- 59) **Gontero P**, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. *Eur Urol.* 2010 Mar;57(3):410-29. Review.
IF: 14.976
- 58) **Gontero P**, Joniau S, Zitella A, Tailly T, Tizzani A, Van Poppel H, Kirkali Z. Ablative therapies in the treatment of small renal tumors: how far from standard of care? *Urol Oncol* 2010;28(3):251-9. Review.
IF: 2.921
- 57) Oderda M, Mondino P, Lucca I, Fiorito C, Gillo A, Zitella A, Greco A, Tizzani A, **Gontero P**. Fatal haematuria in a patient with an orthotopic neobladder and chronic liver failure. *Urol Int* 2009;83(3):368-9.
IF: 1.313
- 56) Oderda M, **Gontero P**. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: is repeat biopsy still necessary? *BJU Int.* 2009;104(11):1554-6.
IF: 4.387
- 55) Mondaini N, Cai T, **Gontero P**, Gavazzi A, Lombardi G, Boddi V, Bartoletti R. Regular moderate intake of red wine is linked to a better women's sexual health. *J Sex Med.* 2009;6(10):2772-7.
IF: 2.844
- 54) Gontero P, Fiorito C, Lucca I, Valentino F, Tizzani A. New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies. *Arch Ital Urol Androl* 2008;80(4):162-6.
IF: 0.91
- 53) Oderda M, Mondino P, Zitella A, Vigna D, Fiorito C, Pacchioni D, Tizzani A, Gontero P. Multipathogenetic origin of a pelvic mass. *Eur Urol* 2009;55(5):1224-8.
IF: 14.976
- 52) van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif C, Kynaston H, Gontero P, Thalmann G, Akdas A, D'haese S, Aaronson N. An international prospective field study of the

EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. *Eur J Cancer* 2009; 44(16):2418-24

IF: 6.163

51) **Gontero P**, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, Mondaini N. Use of penile extender device in the treatment of penile curvature due to Peyronie's disease. Results of a phase II prospective study.

J Sex Med 2009; 6(2):558-66

IF: 2.844

50) **Gontero P**, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, Mondaini N. A pilot phase II prospective study to test the efficacy and tolerability of a penile extender device in the treatment of "short penis".

BJU Int 2009; 103(6):793-7.

IF: 4.387

49) **Gontero P**, Joniau S, Van Poppel H. Radical prostatectomy for PSA over 100 prostate cancer. *Eur Urol* 2009; 54(4):957-8.

IF: 14.976

48) Terrone C, **Gontero P**, Volpe A, Porpiglia F, Bollito E et al. Proposal of an improved classification for pT3 renal cell carcinoma. *J Urol*. 2008 Jul;180(1):72-8

IF: 4.7

47) **Gontero P**, Ceratti G, Guglielmetti S, Andorno A, Terrone C, Bonvini D, Faggiano F, Tizzani A, Frea B, Valente G. Prognostic factors in a prospective series of papillary renal cell carcinomas. *BJU Int*, 2008 May 16

IF: 4.387

46) Sogni F, Brausi M, Frea B, Martinengo C, Faggiano F, Tizzani A, **Gontero P**. Morbidity and Quality of Life in Elderly Patients Receiving Ileal Conduit or Orthotopic Neobladder After Radical Cystectomy for Invasive Bladder Cancer. *Urology*. 2008 May;71(5):919-23

45) Sogni F, Zacchero M, Parola A, Carboni F, Terrone C, **Gontero P**. Sexual function in women undergoing hemodialytic treatment assessed using the female sexual function index and the somatic inkblot series test. *Clin Nephrol*, 2008; 69.

IF: 1.065

44) Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, Rothman M, Gagnon DD, Polverejan E; 3004 Study Group. Premature ejaculation: results from a five-country European observational study.

Eur Urol. 2008 May;53(5):1048-57.

IF: 14.976

43) **Gontero P**, Tizzani A. Intravesical Gemcitabine: State of the Art. *Eur Urol suppl* 2007; 6: 809–815.

IF: 3.364

42) Zitella A, **Gontero P**. Re: Lack of association between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and risk of renal cell carcinoma. *Int Braz J Urol*. 2007;33(6):838-9.

41) Bartoletti R, Cai T, Mondaini N, Dinelli N, Pinzi N, Pavone C, **Gontero P**, Gavazzi A, Giubilei G, Prezioso D, Mazzoli S, Boddi V, Naber KG; Italian Prostatitis Study Group. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multicenter case-control observational study. *J Urol*. 2007 Dec;178(6):2411-5

IF: 4.7

- 40) Gianino MM, Galzerano M, Tizzani A, **Gontero P**. Critical issues in current comparative and cost analyses between retropubic and robotic radical prostatectomy. *BJU Int*. 2008 Jan;101(1):2-3. **IF: 4.387**
- 39) Sogni F, Monga G, Terrone C, **Gontero P**. Primary adenocarcinoma of the rete testis: diagnostic problems and therapeutic dilemmas. *Scand J Urol Nephrol*. 2008;42(1):83-5
IF: 1.243
- 38) Kocjancic E, Crivellaro S, Ranzoni S, Bonvini D, **Gontero P**, Frea B. Adjustable Continence Therapy for the treatment of male stress urinary incontinence: a single-centre study. *Scand J Urol Nephrol*. 2007;41(4):324-8. **IF: 1.243**
- 37) Mondaini N, **Gontero P**, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5 mg and sexual side effects: how many of these are related to a placebo phenomenon? *J Sex Med*. 2007 Nov;4(6):1708-12. **IF: 2.844**
- 36) **Gontero P**, Fontana F, Kocjancic E, Frea B, Tizzani A. Male and female sexual dysfunction (SD) after radical pelvic urological surgery. *ScientificWorldJournal*. 2006;6:2302-14. Review.
- 35) **Gontero P**, Galzerano M, Bartoletti R, Magnani C, Tizzani A, Frea B, Mondaini N. New insights into the pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. *J Urol*. 2007 Aug;178(2):602-7. **IF: 4.7**
- 34) **Gontero P**, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, Mondaini N, Bonvini D, Tizzani A, Frea B. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. *Eur Urol*. 2007;51(4):922-9.
IF: 14.976
- 33) **Mondaini N**, Giubilei G, Ungar A, Gontero P, Cai T, Gavazzi A, Bartoletti R, Geppetti P, Carini M. Alfuzosin (10 mg) does not affect blood pressure in young healthy men. *Eur Urol*. 2006 Dec;50(6):1292-6
IF: 7.667
- 32) **Gontero P**, Frea B. Actual experience and future development of gemcitabine in superficial bladder cancer. *Ann Oncol*. 2006;17 Suppl 5:123-8. Review. **IF: 9.269**
- 31) Valenti G, **Gontero P**, Saccò M, Fontana F, Strollo F, Castellucci A, Heinemann LA. Harmonized Italian version of the Aging Males' Symptoms scale. *Aging Male* 2005;8(3-4):180-3.
- 30) **Gontero P**, Pretti G, Fontana F, Zitella A, Marchioro G, Frea B. Inguinal versus subinguinal varicocele vein ligation using magnifying loupe under local anesthesia: which technique is preferable in clinical practice? *Urology*. 2005;66(5):1075-9. **IF: 2.187**
- 29) **Gontero P**, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. *BJU Int*. 2005 Nov;96(7):970-6. Review.
IF: 4.387
- 28) Kocjancic E, Crivellaro S, Favro M, Ceratti G, Monesi G, Gontero P, Sala M, Giardiello G, Frea B. Sacral neuromodulation for urinary retention in a kidney-transplant patient. *Urol Int*. 2005;75(2):187-8.
IF: 1.313

- 27) **Gontero P**, Masood S, Sogni F, Fontana F, Mufti G, Frea B. Upper urinary tract complications in pregnant women with an ileal conduit. Lessons learned from two cases. *Scand J Urol Nephrol*. 2004;38(6):523-4. **IF: 1.243**
- 26) **Gontero P**, Kirby RS. Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations. *Prostate Cancer Prostatic Dis*. 2005;8(2):133-9. Review. **IF: 3.803**
- 25) **Gontero P**, Fontana F, Zitella A, Montorsi F, Frea B. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. *BJU Int*. 2005 Feb;95(3):359-65. **IF: 4.387**
- 24) Mondaini N, **Gontero P**. Idiopathic short penis: myth or reality? *BJU Int*. 2005 Jan;95(1):8-9. **IF: 4.387**
- 23) **Gontero P**, D'Antonio R, Pretti G, Fontana F, Panella M, Kocjancic E, Allochis G, Frea B. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. *Int J Impot Res*. 2005 Jan-Feb;17(1):80-5. **IF: 1.396**
- 22) **Gontero P**, Sriprasad S, Wilkins CJ, Donaldson N, Muir GH, Sidhu PS. Phentolamine re-dosing during penile dynamic colour Doppler ultrasound: a practical method to abolish a false diagnosis of venous leakage in patients with erectile dysfunction. *Br J Radiol*. 2004 Nov;77(923):922-6. **IF: 1.840**
- 21) Kocjancic E, Tarrano E, Panella M, Crivellaro S, Smith JJ 3rd, Maso G, Favro M, Ceratti G, **Gontero P**, Frea B. Evaluation of minimally invasive analysis system for cough leak point pressure measurement. *J Urol*. 2004 Sep;172(3):994-7. **IF: 4.7**
- 20) **Gontero P**, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC) *Eur Urol*. 2004 Sep;46(3):339-43. **IF: 14.976**
- 19) **Gontero P**, Banisadr S, Frea B, Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. *Eur Urol*. 2004 Sep;46(3):296-311. Review. **IF: 14.976**
- 18) **Gontero P**, Kirby R. Proerectile pharmacological prophylaxis following nerve-sparing radical prostatectomy (NSRP). *Prostate Cancer Prostatic Dis*. 2004;7(3):223-6. **IF: 3.803**
- 17) **Gontero P**, Frea B. Are the current conservative treatments for Peyronie's disease evidence-based? *BJU Int*. 2004 Jul;94(1):3-4. **IF: 4.387**
- 16) **Gontero P**, Kirby R. Early rehabilitation of erectile function after nerve-sparing radical prostatectomy: what is the evidence? *BJU Int*. 2004 May;93(7):916-8. **IF: 4.387**

- 15) Mondaini N, **Gontero P**.
Re: A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. M. Savoie, S. S. Kim and M. S. Soloway.
J Urol. 2004 Jan;171(1):359-60
- 14) **Gontero P**, Muir GH, Frea B.
Pathological findings of penile fractures and their surgical management.
Urol Int. 2003;71(1):77-82. Review. **IF: 1.313**
- 13) **Gontero P**, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, Frea B.
Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study.
J Urol. 2003 Jun;169(6):2166-9. **IF: 4.7**
- 12) **Gontero P**, Sargent JM, Hopster DJ, Lewandowicz GM, Taylor CG, Elgie AW, Williamson CJ, Sriprasad SI, Muir GH.
Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors.
Anticancer Res. 2002 Nov-Dec;22(6C):4073-80. **IF: 1.895**
- 11) Tizzani A, **Gontero P**, Casetta G, Piana P, Baima C, De Zan A, Bodo G, Pacchioni D.
Immunohistochemical evaluation of the safety of transurethral electrovaporization of the prostate and its clinical results.
Prostate Cancer Prostatic Dis. 1999 Jan;2(1):16-20. **IF: 3.803**
- 10) Mondaini N, Ponchiotti R, **Gontero P**, Muir GH, Natali A, Caldarera E, Biscioni S, Rizzo M.
Penile length is normal in most men seeking penile lengthening procedures.
Int J Impot Res. 2002 Aug;14(4):283-6. **IF: 1.396**
- 9) **Gontero P**, Tizzani A, Muir GH, Caldarera E, Macaluso MP.
The genetic alterations in the oncogenic pathway of transitional cell carcinoma of the bladder and its prognostic value.
Urol Res. 2001 Dec;29(6):377-87. Review. **IF: 1.313**
- 8) Masood S, **Gontero P**, Mufti GR.
Hematuria due to immune-mediated thrombocytopenic purpura.
Urol Int. 2001;67(1):80-1. **IF: 1.313**
- 7) Priolo G, **Gontero P**, Martinasso G, Mengozzi G, Formiconi A, Pelucelli G, Zitella A, Casetta G, Viberti L, Aimo G, Tizzani A.
Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer.
Clin Chim Acta. 2001 Mar;305(1-2):47-53. **IF: 2.799**
- 6) **Gontero P**, Sidhu PS, Muir GH.
Penile fracture repair: assessment of early results and complications using color Doppler ultrasound.
Int J Impot Res. 2000 Apr;12(2):125-8; **IF: 1.396**

- 5) Casetta G, **Gontero P**, Zitella A, Pelucelli G, Formiconi A, Priolo G, Martinasso G, Mengozzi G, Aimo G, Viberti L, Tizzani A.
BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Urol Int. 2000;65(2):100-5. **IF: 1.313**
- 4) **Gontero P**, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C, Muir GH, Tizzani A.
Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Eur Urol. 2000 Sep;38(3):287-96. **IF: 14.976**
- 3) **Gontero P**, Muir GH.
Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
Eur Urol. 1998 Dec;34(6):518-9. **Letter**
- 2) Bodo G, **Gontero P**, Casetta G, Alpa M, Brossa G, Russo R, Tizzani A.
Circadian antidiuretic hormone variation in elderly men complaining of persistent nocturia after urinary flow obstruction removal.
Scand J Urol Nephrol. 1998 Sep;32(5):320-4. **IF: 1.243**
- 1) Casetta G, **Gontero P**, Russo R, Pacchioni D, Tizzani A.
p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Eur Urol. 1997;32(2):229-36. **IF: 14.976**

CONGRESS PRESENTATIONS and PRIZES

- **Chairman in several occasions at International Meetings (EAU, EMUC, ESSM)**
- **Presenting author of 50 oral communications and 40 posters in International Meetings**
- **Presenting author of more than 50 communications and posters to Italian Congresses**
- **Prizes:**
 - **Best presentation at the Association of Urology of North Italy, Turin 1998**
 - **Best edited manuscript at the Hot Topic Seminars, Genua, 13 february 2009**
 - **Best poster presentation at the European Association of Urology Congress, Barcellona, 2010, for the research: "Polymorphisms in DNA Repair Genes and Bladder Cancer"**

- Award for the “**Best poster presenter**” at the **American Urological Association Congress, San Francisco, 2010** for the research: “High-risk prostate cancer patients who have specimen-confined disease at pathology have exceptionally good outcomes after surgery”

MEMBERSHIP TO SCIENTIFIC SOCIETIES

Treasurer of the Association of Urology of Piemonte (AUP) (elected in 2010)

Member of the following Scientific Societies:

- Italian Society of Andrology (SIA)
- European Society of Sexual Medicine (ESSM)
- European Association of Urology (EAU)
- Italian Society of Urology (SIU)
- Società Italiana di Urologia Nuova (SUN)
- Associazione Urologi Piemontesi (AUP)
- European Organization for Research and Treatment of Cancer (EORTC-GU):
full membership

BOOKS:

- Author of the book: “ **I marcatori tumorali della vescica** ”
(*Tumour markers in bladder cancer*)
(with A. Tizzani e G. Casetta) Published by Centro Scientifico Editore, 1999.
- Co-author of the Urological part of a text of Emergency Medicine:
“**Medicina d’Urgenza: pratica e progresso**”, Valerio Gai Editor, C.G. Edizioni Medico-Scientifiche, Torino, 2001
- Author of the book: “La riabilitazione erettile dopo prostatectomia radicale. Guida per il paziente” – 2005
- Author of the book chapter “Tumori superficiali della vescica” in: Amadori, Croce “Terapia molecolare in oncologia”, Poletto Editore 2005.
- Co-Editor of the book: **Radical prostatectomy. From open to robotic**. Kirby, Montorsi, Gontero and Smith Jr Editors. Informa Healthcare UK Ltd 2007.
- First Editor of the book: **Problem based urology**. Gontero, Kirby, Carson. Springer-Verlag, London 2013. Two Italian editions from Minerva Medica (2014 and 2016).

PART 2:
CLINICAL AND SURGICAL EXPERIENCE

CLINICAL POSITIONS IN ITALY

- From 6.2000 to 3.2002:
Consultant Urologist, Urology Clinic, University of Piemonte Orientale, Novara, Italy

- From 3.2002 to 30.09.2006:
Senior Lecturer and Consultant Urologist, Urology Clinic, University of Piemonte Orientale, Novara, Italy

- From 1.10.2006 to 31.10.2010:
Senior Lecturer and Consultant Urologist, Urology Clinic, **University of Studies of Torino**, San Giovanni Battista Hospital

- From 1.11.2010 (ongoing position)
Associate Professor of Urology and **Vice Chairmen** of the Urology Clinic, Department of Surgical Sciences, Città della Salute e della Scienza, San Giovanni Battista University Hospital, University of Studies of Torino, Torino, Italy

TRAINING AND CLINICAL POSITIONS ABROAD

- 6-8/1996 “Clinical Fellowship” Department of Urology, University of Tampere, Finland (Prof. T. Tammela).

- 1/98 – 2/99 “Research Registrar” in Urology, King’s College Hospital, London, UK (Mr Coptcoat, Mr Muir)

- 8-10/99 “Specialist Registrar” in Urology, Medway Maritime Hospital, Kent, UK (Mr G. Mufti).

- 1/2000- 4/2000 Staff grade in Urology, Medway Maritime Hospital, Kent, UK

- 5/3/2001 – 1/4/2001 Fellowship Department of Urology, King’s College Hospital di Londra

- 1/11/2003 - 5/5/2004 “Consultant Urologist”, St George Hospital, London, UK** (study leave from University of Piemonte Orientale, Novara, Italy)

SURGICAL TRAINING

- Training in open oncological urology surgery

In 1998 Dr Gontero attends the “Basic surgical skill course”, King’s College Hospital, London. Most of the post-training oncological urological surgical experience is achieved between 2000-2006 performing major oncological surgical procedures and urine diversions under the supervision of Prof. Bruno Frea.

In May 2006 he attends a surgical stage on advanced oncological bladder surgery at the University of Mansoura (Egypt).

In August 2006 he refines the open radical prostatectomy technique under the supervision of Prof H. van Poppel (University of Leuven, Belgium).

- Training in urethral surgery

Dr Gontero attended the Urology Clinic in Leuven (Belgium) performing several urethroplasties under the supervision of Prof Steven Joniau in 2006 and 2007. He also invited Prof Joniau as a visiting professor at Molinette Hospital, Torino, Italy in 2006, 2007 and 2010 and performed, under his supervision, complex cases.

- Training in Laparoscopy

Dr Gontero obtained the basic surgical laparoscopy skill course in 2001 at the Laparoscopic Center in Strasburg. In the following years he achieved competence in laparoscopic kidney surgery under the supervision of Dr Lorenzo Repetto. He also attended international laparoscopic training center such as Memorial Sloan Kettering di New York (Dr Karim Touijer) for the technique of laparoscopic radical prostatectomy. He currently performs around 100 urological laparoscopic procedures per year.

- Training in robotic urological surgery

In 2007 Dr Gontero set up a robotic laparoscopic programme for radical prostatectomy at the San Giovanni Battista Hospital, University of Torino. He refined the technique attending international centers of excellence such as the Global Center of Robotic Surgery of Orlando (USA), directed by Dr Vip Patel in 2009 and 2014 and the Miller University of Miami (Florida) in 2014.

- Training in surgical andrology and penile prosthesis implantation

Since 1998 Dr Gontero has been involved in penile curvature and Peyronie’s disease surgery. In 2002 he was admitted to a Scholarship programme of the Italian Society of Andrology attending stages at the University of Hamburg, Germany (Prof. Fish), Belgrade (Prof. Perovic), Trieste, Italy (Prof. Belgrano) and Milano, Italy (Prof. Austoni).

In 1993 Dr Gontero obtained a Master Degree in Andrological Surgery at the University of Studies of Torino, Italy.

- Training in endourology

Dr Gontero was trained in endourology at King's College Hospital in London in 1998 and at Medway Maritime Hospital (Kent) in 1999 achieving skill in the technique of operative ureteroscopy and transurethral resection of the prostate.

SURGICAL PROCEDURES PERFORMED AS FIRST OPERATOR (1999-)

> 4000 PROCEDURES (first operator)

1600 major surgical procedures (of whom 450 laparoscopic and 300 robotic laparoscopic assisted):

- 690 radical prostatectomies (**260 robotic-assisted, 30 laparoscopic, 400 open**)

- 165 radical cystectomies (40 with an orthotopic neobladder)

- **40 major ablative salvage procedures** (post-radiotherapy radical prostatectomy N=8, salvage retroperitoneal and pelvic lymphadenectomy for testis and prostate cancer N=7, total pelvicctomy for radio- and chemo-recurrent gynaecological cancers N=25)

- **290 partial or radical nephrectomies** for kidney cancer (**170 laparoscopic**, 7 with caval thrombus, 113 open partial or radical nephrectomies)

- **145 non oncological laparoscopic kidney procedures** (30 pyeloplasty, 1 kidney harvesting for auto-transplantation, 30 renal cysts, 4 ureteral re-implantation, 10 pyelolithotomy, 70 extraperitoneal nephrectomies for non-functioning kidneys)

- 120 open procedures for non-oncological kidney diseases

- 125 procedures of reconstructive urology (40 urethroplasties, 22 ureteral reimplantations for iatrogenic or neoplastic reasons, 10 vesico-vaginal fistula, 8 salvage urine diversions, 45 ureteral reimplantations during kidney transplant)

- **70 re-do major surgical procedures** (7 ureteral reimplantations in urine diversions, 15 excisions of recurrent pelvic cancer, 15 ureteral reimplantation for post-surgical stricture, 33 other procedures)

650 intermediate surgical procedures

Among those: Nesbitt procedures (N=40), corporoplasties for Peyronie's disease (N=60), penile prosthesis implantation (N=35), other penile surgical procedures (N=20), artificial urinary sphincter placement (N=8), other procedures (adenomectomies, closure of bladder ruptures) N=480

600 minor surgical procedures

Among those varicocele vein ligations N=150, other procedures (hydroceles, epididymal cysts, orchidectomies, orchidopexis...) N=450

1400 endourological procedures

Among those TURPs N=500, TURBTs N=400, diagnostic and operative N=250, RIRS N=20, other procedures (ureteral stenting, urethrotomies, bladder stones fragmentation...) N=230.

Last updated: November 2016

Signed: Paolo Gontero

A handwritten signature in black ink, appearing to read 'Paolo Gontero'. The signature is stylized with a large loop at the beginning and a long, sweeping tail.